Frontiers in Endocrinology (Jul 2023)
Fibroblast growth factor 21 in metabolic syndrome
- Ming Yang,
- Ming Yang,
- Chongbin Liu,
- Chongbin Liu,
- Na Jiang,
- Na Jiang,
- Yan Liu,
- Yan Liu,
- Shilu Luo,
- Shilu Luo,
- Chenrui Li,
- Chenrui Li,
- Hao Zhao,
- Hao Zhao,
- Yachun Han,
- Yachun Han,
- Wei Chen,
- Wei Chen,
- Li Li,
- Li Li,
- Li Xiao,
- Li Xiao,
- Lin Sun,
- Lin Sun
Affiliations
- Ming Yang
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Ming Yang
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Chongbin Liu
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Chongbin Liu
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Na Jiang
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Na Jiang
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Yan Liu
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Yan Liu
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Shilu Luo
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Shilu Luo
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Chenrui Li
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Chenrui Li
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Hao Zhao
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Hao Zhao
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Yachun Han
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Yachun Han
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Wei Chen
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Wei Chen
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Li Li
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Li Li
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Li Xiao
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Li Xiao
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Lin Sun
- Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
- Lin Sun
- Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- DOI
- https://doi.org/10.3389/fendo.2023.1220426
- Journal volume & issue
-
Vol. 14
Abstract
Metabolic syndrome is a complex metabolic disorder that often clinically manifests as obesity, insulin resistance/diabetes, hyperlipidemia, and hypertension. With the development of social and economic systems, the incidence of metabolic syndrome is increasing, bringing a heavy medical burden. However, there is still a lack of effective prevention and treatment strategies. Fibroblast growth factor 21 (FGF21) is a member of the human FGF superfamily and is a key protein involved in the maintenance of metabolic homeostasis, including reducing fat mass and lowering hyperglycemia, insulin resistance and dyslipidemia. Here, we review the current regulatory mechanisms of FGF21, summarize its role in obesity, diabetes, hyperlipidemia, and hypertension, and discuss the possibility of FGF21 as a potential target for the treatment of metabolic syndrome.
Keywords
